Abstract: Provided herein are compositions and methods comprising anti-CD19 binding agents and methods of using the same for the treatment or amelioration of Immunoglobulin G4-related disease (IgG4-RD). Also provided are compositions and methods of using Inebilizumab for the treatment or amelioration of IgG4-RD and IgG4-RD flare.

Abstract: Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., a fibrotic disease, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an anti-TREM2 antibody or antigen binding fragment thereof.

Abstract: The disclosure provides antibody molecules that bind to TCR V? regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

Abstract: The present disclosure provides for multi-specific antibodies and antigen-binding fragments thereof that bind to human CLDN6 and CD3, a pharmaceutical composition comprising said antibody or antigen-binding fragments thereof, and use of the multi-specific antibody or antigen-binding fragments thereof or the composition for treating a disease, such as cancer.

Abstract: The present disclosure provides for antibodies and antigen-binding fragments thereof that bind to human CD3, a pharmaceutical composition comprising said antibody or antigen-binding fragments thereof, and use of the antibody or antigen-binding fragments thereof or the composition for treating a disease, such as cancer.

Abstract: The invention provided herein relates to methods and uses of a bispecific antibody, which specifically binds the surface antigen CD3 of immune cells and the BCMA antigen on the surface of tumor cells and which may bind to human CD3 with high affinity, induce T cell proliferation, and mediate tumor cell killing effects. The bispecific antibody may be used to mediate the T cell-specific killing of target cells in in vitro tests.

Abstract: Polypeptides for binding to PD-1 and compositions comprising the same, such as targeting to a cell expressing MAdCAM, which can be used, for example as methods and compounds for conferring site-specific or local immune privilege.

Abstract: Antibody molecules that specifically bind to CD138 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.

Abstract: The disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer (SCLC) having a high tumor mutational burden (TMB) status comprising administering to the subject a monotherapy comprising an anti- PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody. The present disclosure also provides a method for identifying a subject suitable for treatment with an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.

Abstract: The present invention provides novel anti-PD-1 antibodies that specifically bind to cell surface PD-1. Also provided are the nucleic acid molecules encoding the anti-PD-1 antibodies, expression vectors and host cells used for the expression of the anti-PD-1 antibodies. The invention further provides the methods for producing the anti-PD-1 antibodies and the use thereof.

Abstract: Provided are an antibody specifically binding to PD-L1 and an antigen-binding fragment thereof. The antibody and the antigen-binding fragment thereof have high specificity and stability, can specifically block a PD-L1-SIPR? pathway, do not cause hemagglutination within a certain concentration range, and thus can significantly suppress tumor growth in vivo.

Abstract: The present disclosure relates to the field of biomedicine, in particular to an anti-PD-L1 antibody and the use thereof. The anti-PD-L1 antibody or the antigen-binding fragment thereof provided in the present disclosure binds to a PD-L1 protein with a high affinity and high specificity, can effectively block the interaction between PD-L1 expressed on a cell surface and PD-1, and has the biological function activity of stimulating the production of cytokine, and has wide application prospects.

Abstract: The present invention generally relates to combinations for use in therapeutic systems and antibody dosage regimens, and uses thereof. Also described herein is a model for predicting if a therapeutic antibody binding to a human target will be associated with a tolerability issue in connection with intravenous administration and/or for predicting if pre-treatment, altered administration route or modification of the antibody can prevent a tolerability issue associated with intravenous administration to a human of the therapeutic antibody. The model comprises administering the antibody intravenously or intraperitoneally to mice and observing the mice immediately after the administration for any transient display of the macroscopic symptoms isolation and decreased activity.

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Abstract: The invention provides a method of treating or reducing the severity of thyroid-associated ophthalmopathy (TAO), also known as thyroid eye disease (TED) or Graves' ophthalmopathy or orbitopathy (GO), as well as antibodies, or antigen binding fragments thereof, and pharmaceutical compositions comprising them, useful in the methods.

Abstract: The invention provides method of treating fibrosis, comprising the steps of (a) selecting a TGF? inhibitor for the treatment of fibrosis, (1) wherein the TGF? inhibitor (A) specifically binds a LTBP1-proTGF? complex; (B) does not bind a human GARP-proTGF? complex; (C) does not bind a human LRRC33-proTGFp complex; and (D) does not bind mature TGF?1, mature TGF?2 or mature TGF?3; and (2) wherein the TGF? inhibitor is selected using an assay to measure the amount of a marker, wherein the amount of the marker is indicative of the treatment of fibrosis, with the proviso that the marker is not pSmad2; and (b) providing the selected TGF? inhibitor for administration to a subject in need of treatment for fibrosis. These selected TGF? inhibitor are isoform-specific, context-selective inhibitors of TGF?1 that selectively target matrix-associated TGF?1 activation but not immune cell-associated TGF?1 activation.

Abstract: The invention provides methods, uses and compositions for the treatment of hidradenitis suppurativa. The invention describes methods and uses for treating hidradenitis suppurativa with anti-interleukin 36R (anti-IL36R) antibodies. Also described are methods for determining the efficacy of anti-IL36R antibodies for treating hidradenitis suppurativa in a subject.

Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.

Abstract: Disclosed herein are human antibody molecules that immunospecifically bind to human CXCR2. The disclosed human antibody molecules are potent and selective antagonists of CXCR2 functions and prevent the recruitment of neutrophils into tissues without strongly depleting circulating neutrophil numbers. Pharmaceutical compositions, nucleic acid molecules, vectors, cells, and uses of the disclosed antibodies are also provided.

Abstract: The present invention provides an anti-OX40 antibody or antigen-binding fragment thereof, a preparation method therefor and the use for treating OX40-related diseases or conditions.

Abstract: Provided are methods of clinical treatment of diffuse large B-cell lymphoma (DLBCL) (e.g., previously untreated, high-risk DLBCL) in human subjects using a bispecific antibody which binds to CD3 and CD20 in combination with standard of care regimen of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone).

Abstract: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human CD20. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such nucleic acid molecules. The invention further relates to methods for producing the ABMs of the invention, and to methods of using these ABMs in treatment of disease. In addition, the present invention relates to ABMs with modified glycosylation having improved therapeutic properties, including antibodies with increased Fc receptor binding and increased effector function.

Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.

Abstract: Provided are humanized anti-human CD45 antibodies and pharmaceutical compositions including the antibodies.

Abstract: Provided herein are, inter alia, methods for treating oncovirus-positive cancers using anti-CD73 compounds, such as anti-CD73 antibodies. Exemplary oncovirus include human papilloma virus, hepatitis, cytomegalovirus, Epstein-Barr virus, human immunodeficiency virus, human herpes virus-8, polyomavirus, adenovirus, human T-cell leukemia virus, and the like.

Abstract: Disclosed are methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics.

Abstract: Monoclonal antibodies that bind glypican-2 (GPC2) with high affinity are described. Immunotoxins and chimeric antigen receptors (CARs) that include the disclosed antibodies or antigen-binding fragments thereof are further described. In some instances, the antibody or antigen-binding fragment is humanized. The disclosed GPC2-specific antibodies and conjugates can be used, for example, for the diagnosis or treatment of GPC2-positive cancers, including neuroblastoma, medulloblastoma and retinoblastoma.

Abstract: Provided is a humanized antibody or antigen-binding fragment that specifically binds to GPC3. The antibody or antigen-binding fragment has high affinity with GPC3 protein, and can be used in the preparation of drugs for treating tumors and the like. Also provided are a nucleic acid molecule encoding the humanized GPC3 antibody or antigen-binding fragment, an expression vector, a host cell, and a method for preparing the antibody or antigen-binding fragment. Also provided are an immunoconjugate comprising same, a chimeric antigen receptor, an immunocompetent cell, a multispecific molecule, and a pharmaceutical composition. Also provided are a method for detecting GPC3, and a method for treating various GPC3-related disorders including hepatocellular carcinoma.

Abstract: The present disclosure relates to antibodies that specifically bind to a tumor-associated antigen (TAA) such as PSMA and/or CD3, including bispecific antibodies that bind to a TAA (e.g., PSMA) and CD3, and compositions comprising the same. These antibodies are useful for enhancing immune responses and for the treatment of disorders, including solid tumor cancers, for example, by increasing tumor localization.

Abstract: The disclosure provides novel antigen-binding proteins that bind STEAP1 and methods of use.

Abstract: Provision of a chimeric antigen receptor (CAR) comprising a disialoganglioside (GD2)-binding domain which comprises?a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences:?b) a light chain variable region (VL) having CDRs with the following sequences: T cells expressing such a CAR are useful in the treatment of some cancers.

Abstract: The present invention relates to a nucleic acid nanostructure comprising a first surface and a second surface, wherein said first surface and said second surface are located at opposing sides of said nanostructure, wherein said first surface comprises at least a first targeting agent and said second surface comprises at least a second targeting agent and at least a third targeting agent. The present invention further relates to a composition comprising a nucleic acid nanostructure. The invention also relates to a nanostructure and a composition for use in medicine, and to a nanostructure and a composition for use in a method of preventing or treating a disease. Furthermore, the present invention relates to a method of preparing a nanostructure and to a use of a nanostructure for binding first target and the second target.

Abstract: Compositions and methods for treating a medical condition are provided. Accordingly, there is provided a composition comprising a polypeptide comprising a GnRH receptor binding protein and a polynucleotide coding a therapeutic agent, wherein said polypeptide is in association with said polynucleotide via a linker comprising a cleavage motif that can be cleaved by a proteolytic enzyme secreted by a cell expressing said GnRH receptor. Also provided is a nucleic acid construct comprising a nucleic acid sequence encoding a fusion protein comprising a DNA binding domain (DBD) of a transcription factor that binds a regulatory region of a gonadotropin gene attached to a chromatin modifying domain that represses transcription upon association with the DBD. Also provided are methods of use thereof.

Abstract: Carboxymethyl cellulose of improved storage stability is produced by a process which comprises the steps of a) reacting cellulose with an alkalization agent in the presence of water and one or more organic solvents, wherein the total amount of organic solvent(s) is at least 50 weight percent, based on total weight of cellulose, water and organic solvent(s); b) reacting the alkalized cellulose with monohaloacetic acid or a salt thereof to produce a reaction mixture comprising a carboxymethyl cellulose salt, water and one or more organic solvents; c) adding acid to the reaction mixture from step b) to produce a carboxymethyl cellulose having a pH of from 6 to 10, when dissolved in water at a concentration of 1 weight percent at a temperature of 25° C., and d) during and/or after acid addition in step c), subjecting the reaction mixture to shearing at a shear rate of at least 800 s?1.

Abstract: Provided herein are methods of producing heparin and heparan sulfate from modified cells, such as modified MST cells, and compositions comprising heparin and heparan sulfate isolated from modified cells.

Abstract: Disclosed herein are compounds of the formula: A-L-R1(I), wherein the these variables are defined herein, as well as medical devices comprising said compounds. The present disclosure also provides pharmaceutical compositions comprising the compounds or medical devices disclosed herein. Further, the present disclosure provides methods of treatment using the compounds, medical devices, or pharmaceutical compositions disclosed herein.

Abstract: The embodiments of the present disclosure provide a method for extracting xylose liquid and cellulose with high purity from corn straw. The method includes raw material screening, raw material preprocessing, alkali processing, acid hydrolysis, and gradient alkali processing. The embodiments of the present disclosure adopt a gradient selective refining method for extracting a high-purity xylose liquid and cellulose from the corn straw, so as to maximize the extraction of the xylose from the corn straw, and at the same time, to separate and extract a high-purity cellulose product from straw residue under a low-cost process processing.

Abstract: Provided is a thermal decomposition method of used rubber that has excellent yields of isoprene and limonene without reducing the efficiency of thermal decomposition. The method is a method of thermally decomposing used rubber, including bringing the used rubber into contact with or swelling the used rubber in a medium, where the medium has a SP value of 8.3 (cal/cm3)1/2 to 11 (cal/cm3)1/2 and an endothermic peak temperature of 235° C. or higher measured by thermogravimetry (TGA), and the medium is liquid at 150° C., and then performing thermal decomposition.

Abstract: Provided is a method by which a crosslinking site of a crosslinked elastomer can easily be returned to a non-crosslinked state. The method of returning a crosslinking site of a crosslinked elastomer to a non-crosslinked state includes a step of causing contact of a crosslinked elastomer including a diboronic acid ester skeleton unit represented by a specific general formula (1) at a crosslinking site with a monoboronic acid compound represented by a specific general formula (3) in the presence of an organic solvent having an SP value (solubility parameter) of not less than 7 (cal/cm3)1/2 and not more than 10 (cal/cm3)1/2. In this step, a molar abundance ratio of the monoboronic acid compound relative to the diboronic acid ester skeleton unit (monoboronic acid compound/diboronic acid ester skeleton unit) is set as more than 2 and not more than 5.

Abstract: The current invention provides a novel method to synthesize a mono-disperse non-porous polymer particles with a unique gradient composition from the core to the shell. In particular, the present invention offers the flexibility to design the chemical and physical properties of different sections of the particle. This flexibility allows for significant latitude in the design of particles for analyzing a large variety of samples in different fields—through using these particles in different chromatography techniques including, but not limited to, ion exchange HPLC (e.g., bio-separation at different modes), reversed-phase HPLC, narrow bore and capillary HPLC, hydrophilic/hydrophobic interaction liquid chromatography, capillary electrochromatography separation, and two dimensional liquid chromatography.

Abstract: The present disclosure is directed to novel methods of oxidizing polymers, such as polystyrene, using ozone, and deconstructing such polymers using ozone, to provide oligomeric product compounds, compounds made according to said methods, homopolymers and heteropolymers derived from said compounds, and compositions comprising said homopolymers and heteropolymers.

Abstract: Ethylene-based polymers having a melt index from 0.8 to 8 g/10 min, a density from 0.94 to 0.96 g/cm3, and a ratio of Mw/Mn from 6 to 20 are disclosed. These polymers can have one or more of an environmental stress crack resistance (ESCR) of at least 5,000 hr (condition A, 100% Igepal), an ESCR of at least 2,500 hr (condition A, 10% Igepal), a CY-a parameter from 0.35 to 0.53, a PSP2 value from 5 to 8.5, a tan ? at 0.1 sec?1 from 8 to 24 degrees, a Mz from 275,000 to 420,000 g/mol, an IVc from 2 to 3 dL/g, a strain hardening modulus (SHM) from 19 to 47 MPa, and/or an amount of polymer eluting between 93 and 95° C. in an ATREF profile of from 7 to 30 wt. %.

Abstract: A method for producing a heterophasic propylene polymerization material, including: a first polymerization step of forming a polymer (I) by polymerizing propylene in presence of a contact product and an olefin polymerization catalyst obtained by bringing an aluminum compound into contact with an olefin polymerization-use solid catalyst component containing a titanium atom, a magnesium atom, a halogen atom, and an internal electron donor; and a second polymerization step of forming a polymer (II) by copolymerizing propylene with at least one kind selected from the group consisting of ethylene and C4-12 ?-olefins in presence of the polymer (I). The contact product can be obtained by bringing an aluminum compound into contact with a specific antioxidant.

Abstract: Disclosed herein are methods for synthesis of ultra-high molecular weight polyethylene (UHMWPE), with improved disentanglement, for solid-state processing into a product, such as tapes, films, and ropes, etc., with superior mechanical properties. The method includes using a catalyst support which includes MgCl2 pre-reacted with different alcohols. The MgCl2/alcohol adducts are reacted with different aluminum alkyls to form nanoparticles support, preferably in-situ, under inert environment in the presence of the monomer used to synthesize the UHMWPE. The resulting heterogeneous catalytic system and polymer synthesis method results in improved UHMWPE with high average molecular weight (Mw)>1 million g/mol, with lower levels of entanglement (while avoiding fouling seen with homogenous catalytic systems), allowing for processing into products such as tapes with superior mechanical properties.

Abstract: The invention relates to a type I photoinitiator for the free-radical curing of radiation-curable compositions. In particular, the invention relates to a silicone composition comprising a type I photoinitiator and an organopolysiloxane having at least one (meth)acrylate group.

Abstract: In a method of producing an ethylene-carboxylic acid copolymer, an ethylene monomer and a carboxylic acid comonomer are supplied to a reactor. The ethylene monomer and the carboxylic acid comonomer are copolymerized using a chain transfer agent represented by a specific chemical formula to form the ethylene-carboxylic acid copolymer.

Abstract: The disclosure relates to a process for polymerising olefins in multi stage polymerisation process configuration, comprising a) polymerising in a first polymerisation step first olefin monomer, optionally in the presence of at least one other alpha olefin monomer, in the presence of a polymerisation catalyst so as to form a first polymer component (A), and b) polymerising in a second polymerisation step in gas phase second olefin monomer, optionally in the presence of at least one other alpha olefin comonomer, in the presence of the first polymer component (A) of step a) and an induced swelling agent, so as to for a second polymer component (B), wherein the first polymer component (A) and the second polymer component (B) are produced at production rates meeting a predetermined target weight ratio of the second polymer component (B) to the first polymer component (A), the process comprising the steps of: i) determining a first weight ratio of the second polymer component (B) to the first polymer component (A)

Abstract: A vinylidene fluoride copolymer composition having stable dispersibility in a dispersion medium over a long period of time, the composition having a melting temperature of 140° C. or lower, a reversing heat flow of the composition has endothermic peaks having an amount of enthalpy of fusion of 2 J/g or more, and an absolute value of a difference between a temperature showing a largest endothermic peak among the endothermic peaks and the melting temperature of the composition is 10° C. or lower. When a dispersion containing butyl butyrate and the vinylidene fluoride copolymer composition (vinylidene fluoride content rate of 10 mass %) is left to stand for 20 hours, a content rate of the vinylidene fluoride copolymer composition in an upper 20 vol % of the dispersion after the dispersion is left to stand is 4.0 mass % or more and 10 mass % or less.

Abstract: A method for tailoring mechanical properties of a photopolymer includes providing an active monomer feedstock, adding a sulfur-free chain transfer agent (CTA) to the active monomer feedstock to form a mixture, and curing the mixture under predetermined conditions. The sulfur-free CTA includes a Cobalt(II) complex or a Cobalt(III) complex, the mechanical properties include glass transition temperature, crosslinking density, and/or conversion rate, and a concentration of the sulfur-free CTA is less than 30% of the mixture. The predetermined conditions include intensity, wavelength, and application time of energy from a light source, a cure temperature, and/or the concentration of the sulfur-free CTA in the mixture. The method may further include adding a diluent to the mixture to modify a viscosity of the active monomer feedstock. The diluent may include one of a reactive diluent and a non-reactive diluent, such as methyl methacrylate (MMA) and methacrylate (MA).

Abstract: An acrylic rubber having at least one cross-linkable group-containing monomer unit selected from the group including carboxyl group-containing monomer units, halogen atom-containing monomer units, and epoxy group-containing monomer units, and an (meth)acrylamide monomer units, wherein the amount of the (meth)acrylamide monomer unit is 0.2 to 17.5% by weight of the total monomer units.